methane has been researched along with Colitis, Mucous in 48 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 9.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| "Whether hydrogen and methane gas produced during lactulose breath test (LBT) are associated with symptoms of irritable bowel syndrome (IBS) is not determined." | 9.17 | Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test. ( Choi, HS; Hahm, JS; Jun, DW; Koh, DH; Lee, HL; Lee, KN; Lee, OY; Lee, SP; Sohn, W; Yoon, BC, 2013) |
| " This subanalysis was done on the constipation-predominant IBS subgroup of patients (C-IBS) to test the ability of neomycin to improve constipation and its correlation with the elimination of methane on breath test." | 9.12 | Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. ( Chatterjee, S; Chow, EJ; Kong, Y; Park, S; Pimentel, M, 2006) |
| "Methane on LBT is associated with constipation both subjectively and objectively." | 9.12 | The degree of breath methane production in IBS correlates with the severity of constipation. ( Chatterjee, S; Kong, Y; Low, K; Park, S; Pimentel, M, 2007) |
| "Lactose intolerance is the most prevalent intestinal malabsorption disorder." | 8.91 | [Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015) |
| "We found that constipation and bloating severity did not correlate with methane levels on GBT." | 7.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C)." | 7.88 | Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation. ( Bristol, A; Chadwick, A; Coughlin, O; Hubert, S; Kokai-Kun, J; Wacher, V, 2018) |
| "Patients with irritable bowel syndrome (IBS) can be assigned to groups with different gastrointestinal (GI) symptoms based on results from a combined nutrient and lactulose challenge." | 7.83 | Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. ( Brazeilles, R; Derrien, M; Guyonnet, D; Le Nevé, B; Ohman, L; Simrén, M; Tap, J; Törnblom, H, 2016) |
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 7.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 7.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 7.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| " Among these findings, methane production is more commonly associated with constipation-predominant symptoms." | 7.76 | Evaluating breath methane as a diagnostic test for constipation-predominant IBS. ( Hwang, L; Khoshini, R; Low, K; Makhani, M; Melmed, G; Pimentel, M; Pokkunuri, V; Sahakian, A, 2010) |
| "To assess the prevalence of small intestinal bacterial overgrowth (SIBO) in children affected by irritable bowel syndrome (IBS)." | 7.75 | Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. ( Fundarò, C; Gabrielli, M; Gasbarrini, A; Giorgio, V; Lauritano, EC; Pantanella, A; Scarpellini, E, 2009) |
| " The present study was designed to evaluate the effect of predominant fasting methane CH(4) or H(2) production on the outcome of lactose HBT, in a large, homogeneous series of adult patients with irritable bowel syndrome (IBS)." | 7.72 | Effect of predominant methanogenic flora on the outcome of lactose breath test in irritable bowel syndrome patients. ( Camillo, MD; Caprilli, R; Marinaro, V; Vernia, P, 2003) |
| "4% and specificity of 100% for diagnosing IMO on the glucose and lactulose breath tests and was associated with constipation (5." | 5.51 | A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth. ( Chang, C; Hosseini, A; Kowalewski, E; Leite, G; Mathur, R; Morales, W; Pimentel, M; Rao, S; Rashid, M; Rezaie, A; Sanchez, M; Takakura, W; Torosyan, J; Villanueva-Millan, MJ; Wang, J, 2022) |
| "Rifaximin, although superior for the treatment of irritable bowel syndrome compared with other antibiotics, seems less effective in methane-positive subjects." | 5.36 | A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. ( Hua, J; Hwang, L; Low, K; Morales, W; Pimentel, M; Zhu, A, 2010) |
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 5.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| " In children with IBS, lactulose breath test hydrogen and methane production did not, however, correlate with abdominal pain, IBS subtype, or psychosocial distress." | 5.24 | Lactulose Breath Test Gas Production in Childhood IBS Is Associated With Intestinal Transit and Bowel Movement Frequency. ( Chumpitazi, BP; Shulman, RJ; Weidler, EM, 2017) |
| " Methane production is associated with constipation and its severity in constipation-predominant IBS (C-IBS)." | 5.19 | Antibiotic treatment of constipation-predominant irritable bowel syndrome. ( Amichai, M; Chang, C; Chua, KS; DiBaise, J; Mirocha, J; Pimentel, M; Rao, S, 2014) |
| "Whether hydrogen and methane gas produced during lactulose breath test (LBT) are associated with symptoms of irritable bowel syndrome (IBS) is not determined." | 5.17 | Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test. ( Choi, HS; Hahm, JS; Jun, DW; Koh, DH; Lee, HL; Lee, KN; Lee, OY; Lee, SP; Sohn, W; Yoon, BC, 2013) |
| " This subanalysis was done on the constipation-predominant IBS subgroup of patients (C-IBS) to test the ability of neomycin to improve constipation and its correlation with the elimination of methane on breath test." | 5.12 | Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. ( Chatterjee, S; Chow, EJ; Kong, Y; Park, S; Pimentel, M, 2006) |
| "Methane on LBT is associated with constipation both subjectively and objectively." | 5.12 | The degree of breath methane production in IBS correlates with the severity of constipation. ( Chatterjee, S; Kong, Y; Low, K; Park, S; Pimentel, M, 2007) |
| "Lactose intolerance is the most prevalent intestinal malabsorption disorder." | 4.91 | [Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015) |
| "Consecutive Asian adults with Rome III diagnosed common FGIDs (functional dyspepsia/FD, IBS and functional constipation/FC) and non-FGID controls were subjected to glucose breath testing, with hydrogen (H2) and methane (CH4) levels determined." | 4.12 | Small Intestinal Bacterial Overgrowth In Various Functional Gastrointestinal Disorders: A Case-Control Study. ( Beh, KH; Chong, SCS; Chuah, KH; Lee, YY; Lim, SZ; Mahadeva, S; Tan, PO; Thalha, AM; Wong, MS; Zulkifli, KK, 2022) |
| "We found that constipation and bloating severity did not correlate with methane levels on GBT." | 3.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C)." | 3.88 | Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation. ( Bristol, A; Chadwick, A; Coughlin, O; Hubert, S; Kokai-Kun, J; Wacher, V, 2018) |
| "Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time." | 3.83 | Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. ( Adler, M; Dhingra, S; Guttermuth, C; Kasir, R; Lee, A; Zakko, P; Zakko, S, 2016) |
| "Patients with irritable bowel syndrome (IBS) can be assigned to groups with different gastrointestinal (GI) symptoms based on results from a combined nutrient and lactulose challenge." | 3.83 | Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. ( Brazeilles, R; Derrien, M; Guyonnet, D; Le Nevé, B; Ohman, L; Simrén, M; Tap, J; Törnblom, H, 2016) |
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 3.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 3.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 3.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| " Among these findings, methane production is more commonly associated with constipation-predominant symptoms." | 3.76 | Evaluating breath methane as a diagnostic test for constipation-predominant IBS. ( Hwang, L; Khoshini, R; Low, K; Makhani, M; Melmed, G; Pimentel, M; Pokkunuri, V; Sahakian, A, 2010) |
| "To assess the prevalence of small intestinal bacterial overgrowth (SIBO) in children affected by irritable bowel syndrome (IBS)." | 3.75 | Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. ( Fundarò, C; Gabrielli, M; Gasbarrini, A; Giorgio, V; Lauritano, EC; Pantanella, A; Scarpellini, E, 2009) |
| "We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs." | 3.72 | IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. ( Kong, Y; Park, S; Pimentel, M, 2004) |
| " The present study was designed to evaluate the effect of predominant fasting methane CH(4) or H(2) production on the outcome of lactose HBT, in a large, homogeneous series of adult patients with irritable bowel syndrome (IBS)." | 3.72 | Effect of predominant methanogenic flora on the outcome of lactose breath test in irritable bowel syndrome patients. ( Camillo, MD; Caprilli, R; Marinaro, V; Vernia, P, 2003) |
| "Reduction of short-chain poorly absorbed carbohydrates (FODMAPs) in the diet reduces symptoms of irritable bowel syndrome (IBS)." | 2.75 | Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. ( Barrett, JS; Biesiekierski, JR; Gibson, PR; Irving, PM; Mitchell, SB; Muir, JG; Ong, DK; Shepherd, SJ; Smith, S, 2010) |
| "Hydrogen was detected more frequently in patients with diarrhea-predominant IBS (OR, 8; 95% CI, 1." | 1.36 | Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? ( McCallum, RW; Reddymasu, SC; Sostarich, S, 2010) |
| "Rifaximin, although superior for the treatment of irritable bowel syndrome compared with other antibiotics, seems less effective in methane-positive subjects." | 1.36 | A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. ( Hua, J; Hwang, L; Low, K; Morales, W; Pimentel, M; Zhu, A, 2010) |
| "Methane and H(2) were measured using an SC Microlyser from Quintron, USA, at baseline and every 30 min for a total of 4 h." | 1.35 | Effect of predominant methanogenic flora on outcome of lactose hydrogen breath test in controls and irritable bowel syndrome patients of north India. ( Bhasin, DK; Kaur, H; Rana, SV; Sharma, S; Singh, K; Sinha, SK, 2009) |
| "Flatulence is a common symptom in patients with irritable bowel syndrome (IBS)." | 1.35 | Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India. ( Kaur, H; Rana, SV; Sharma, S; Sikander, A; Singh, K; Sinha, SK, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (18.75) | 29.6817 |
| 2010's | 32 (66.67) | 24.3611 |
| 2020's | 7 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Takakura, W | 1 |
| Pimentel, M | 11 |
| Rao, S | 2 |
| Villanueva-Millan, MJ | 1 |
| Chang, C | 4 |
| Morales, W | 3 |
| Sanchez, M | 1 |
| Torosyan, J | 1 |
| Rashid, M | 1 |
| Hosseini, A | 1 |
| Wang, J | 1 |
| Leite, G | 1 |
| Kowalewski, E | 1 |
| Mathur, R | 1 |
| Rezaie, A | 1 |
| Algera, JP | 1 |
| Colomier, E | 1 |
| Melchior, C | 1 |
| Hreinsson, JP | 1 |
| Midenfjord, I | 1 |
| Clevers, E | 1 |
| Simrén, M | 4 |
| Törnblom, H | 4 |
| Linlawan, S | 1 |
| Patcharatrakul, T | 1 |
| Somlaw, N | 1 |
| Gonlachanvit, S | 1 |
| Essa, H | 1 |
| Hamdy, S | 1 |
| Green, D | 1 |
| Lal, S | 1 |
| McLaughlin, J | 1 |
| Hoffmann, S | 1 |
| Leitao, E | 1 |
| Paine, P | 1 |
| Eetemadi, A | 1 |
| Tagkopoulos, I | 1 |
| Yu, X | 1 |
| Li, Y | 1 |
| Xiang, F | 1 |
| Feng, J | 1 |
| Chuah, KH | 1 |
| Wong, MS | 1 |
| Tan, PO | 1 |
| Lim, SZ | 1 |
| Beh, KH | 1 |
| Chong, SCS | 1 |
| Zulkifli, KK | 1 |
| Thalha, AM | 1 |
| Mahadeva, S | 1 |
| Lee, YY | 1 |
| Chumpitazi, BP | 2 |
| McMeans, AR | 1 |
| Vaughan, A | 1 |
| Ali, A | 1 |
| Orlando, S | 1 |
| Elsaadi, A | 1 |
| Shulman, RJ | 2 |
| Hubert, S | 1 |
| Chadwick, A | 1 |
| Wacher, V | 2 |
| Coughlin, O | 1 |
| Kokai-Kun, J | 1 |
| Bristol, A | 1 |
| Chen, AGY | 1 |
| Offereins, MSL | 1 |
| Mulder, CJ | 1 |
| Frampton, CM | 1 |
| Gearry, RB | 1 |
| Le Nevé, B | 3 |
| Derrien, M | 3 |
| Tap, J | 3 |
| Brazeilles, R | 3 |
| Cools Portier, S | 1 |
| Guyonnet, D | 2 |
| Ohman, L | 3 |
| Störsrud, S | 2 |
| Singh, P | 1 |
| Duehren, S | 1 |
| Katon, J | 1 |
| Rangan, V | 1 |
| Ballou, S | 1 |
| Patel, R | 1 |
| Iturrino, J | 1 |
| Lembo, A | 1 |
| Nee, J | 1 |
| de Lacy Costello, BP | 1 |
| Ledochowski, M | 1 |
| Ratcliffe, NM | 1 |
| Lee, KN | 1 |
| Lee, OY | 1 |
| Koh, DH | 1 |
| Sohn, W | 1 |
| Lee, SP | 1 |
| Jun, DW | 1 |
| Lee, HL | 1 |
| Yoon, BC | 1 |
| Choi, HS | 1 |
| Hahm, JS | 1 |
| Berg, LK | 1 |
| Fagerli, E | 1 |
| Martinussen, M | 1 |
| Myhre, AO | 1 |
| Florholmen, J | 1 |
| Goll, R | 1 |
| Chua, KS | 1 |
| Mirocha, J | 2 |
| DiBaise, J | 1 |
| Amichai, M | 1 |
| Ghoshal, UC | 2 |
| Srivastava, D | 2 |
| Ghoshal, U | 2 |
| Misra, A | 1 |
| Di Stefano, M | 1 |
| Mengoli, C | 1 |
| Bergonzi, M | 1 |
| Klersy, C | 1 |
| Pagani, E | 1 |
| Miceli, E | 1 |
| Corazza, GR | 1 |
| Pozuelo, M | 1 |
| Panda, S | 1 |
| Santiago, A | 1 |
| Mendez, S | 1 |
| Accarino, A | 1 |
| Santos, J | 1 |
| Guarner, F | 1 |
| Azpiroz, F | 1 |
| Manichanh, C | 1 |
| Kasir, R | 1 |
| Zakko, S | 1 |
| Zakko, P | 1 |
| Adler, M | 1 |
| Lee, A | 1 |
| Dhingra, S | 1 |
| Guttermuth, C | 1 |
| Buzás, GM | 1 |
| Gottlieb, K | 1 |
| Sliman, J | 1 |
| Long, SK | 1 |
| Di Palma, JA | 1 |
| Weidler, EM | 1 |
| Shukla, R | 1 |
| Cools-Portier, S | 1 |
| Doré, J | 1 |
| Rana, SV | 2 |
| Sinha, SK | 2 |
| Sharma, S | 2 |
| Kaur, H | 2 |
| Bhasin, DK | 1 |
| Singh, K | 2 |
| Hwang, L | 3 |
| Low, K | 4 |
| Khoshini, R | 1 |
| Melmed, G | 1 |
| Sahakian, A | 1 |
| Makhani, M | 2 |
| Pokkunuri, V | 1 |
| Scarpellini, E | 1 |
| Giorgio, V | 1 |
| Gabrielli, M | 1 |
| Lauritano, EC | 1 |
| Pantanella, A | 1 |
| Fundarò, C | 1 |
| Gasbarrini, A | 1 |
| Attaluri, A | 1 |
| Jackson, M | 1 |
| Valestin, J | 1 |
| Rao, SS | 1 |
| Hua, J | 1 |
| Zhu, A | 1 |
| Reddymasu, SC | 1 |
| Sostarich, S | 1 |
| McCallum, RW | 2 |
| Gwee, KA | 1 |
| Ong, DK | 1 |
| Mitchell, SB | 1 |
| Barrett, JS | 1 |
| Shepherd, SJ | 1 |
| Irving, PM | 1 |
| Biesiekierski, JR | 1 |
| Smith, S | 1 |
| Gibson, PR | 1 |
| Muir, JG | 1 |
| Yang, J | 1 |
| Petrone, P | 1 |
| Sarkisyan, G | 1 |
| Fernández, M | 1 |
| Coloma, E | 1 |
| Akopian, G | 1 |
| Ortega, A | 1 |
| Kaufman, HS | 1 |
| Kim, G | 1 |
| Deepinder, F | 1 |
| Weitsman, S | 1 |
| Gunsalus, R | 1 |
| Furnari, M | 1 |
| Savarino, E | 1 |
| Bruzzone, L | 1 |
| Moscatelli, A | 1 |
| Gemignani, L | 1 |
| Giannini, EG | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Bajaj, JS | 1 |
| Gillevet, PM | 1 |
| Hylemon, PB | 1 |
| Vernia, P | 1 |
| Camillo, MD | 1 |
| Marinaro, V | 1 |
| Caprilli, R | 1 |
| Kong, Y | 3 |
| Park, S | 3 |
| Chatterjee, S | 2 |
| Chow, EJ | 1 |
| Morken, MH | 1 |
| Berstad, AE | 1 |
| Nysaeter, G | 1 |
| Berstad, A | 1 |
| Majewski, M | 1 |
| Sikander, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiome Fructan Metabolism and Symptom Generation in Childhood IBS[NCT02842281] | 55 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| Association Between GI Microbiota, Low-grade Inflammation and Classical Pathophysiological Factors in Patients With Irritable Bowel Syndrome (IBS) and Effect of the Consumption of Activia on GI Symptoms Provoked by a Lactulose Challenge Test in IBS Patien[NCT01252550] | 100 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)[NCT04501380] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-06-30 | Enrolling by invitation | ||
| Butyrate in Children With IBS: Double Blind Placebo Controlled Randomized Clinical Trial[NCT04566679] | 50 participants (Anticipated) | Interventional | 2021-04-21 | Recruiting | |||
| Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation[NCT03117322] | Phase 4 | 40 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome[NCT03462966] | Phase 2 | 4 participants (Actual) | Interventional | 2018-07-01 | Terminated (stopped due to recruitment challenges) | ||
| Randomized Controlled Trial of Food Elimination Based on IgG Antibodies for Treatment of Functional Gastrointestinal Diseases (FGIDs) in Children[NCT02565355] | 60 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Effect of Physical Form of Apples on Gastrointestinal Function and Satiety: a MRI Study[NCT03714464] | 31 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Effects of FODMAPs (Fermentable Oligo-, Di-, and Mono-saccharides, And Polyols) on Small Bowel Water Content: an MRI Study[NCT01459406] | 17 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia[NCT02863822] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn (stopped due to no patients enrolled) | |||
| Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea[NCT04557215] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2020-11-13 | Completed | ||
| Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome[NCT00945334] | 37 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| The Effects of Rifaximin Therapy in Patients Pre-Diagnosed With Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo Controlled Study[NCT02009618] | 500 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | Millimetre of mercury (Mean) |
|---|---|
| Therapeutic | 106 |
A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | volume cubic centimeter (Mean) |
|---|---|
| Therapeutic | 37.5 |
"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin
| Intervention | Participants (Count of Participants) |
|---|---|
| Therapeutic | 2 |
"Change in severity of abdominal pain from baseline, as determined from weekly average visual analog scale (VAS) scores, relative to Rifaximin alone. VAS scores allows subject to choose 0 for no pain to 100 pain as bad as it could possibly be.~The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 no pain and 100 pain as bad as it could possibly be~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Rifaximin 550 mg | -5.43 |
| Rifaximin 200 mg + Placebo | -8.90 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -5.59 |
"Change in stool form from baseline, as determined from stool diary data comparing Rifaximin alone vs rifaximin and NAC~The Bristol Stool Chart, the minimum value is 1 (means constipation) and maximum value is 7 (means diarrhea).~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Rifaximin 550 mg | -0.26 |
| Rifaximin 200 mg + Placebo | -0.45 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -0.49 |
"Change in stool frequency from baseline, as determined from diary data comparing Rifaximin alone vs Rifaximin and NAC~determined from daily stool diary data~The change in bowel movements/day between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | number of bowel movements (Mean) |
|---|---|
| Rifaximin 550 mg | -0.04 |
| Rifaximin 200 mg + Placebo | -0.50 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -0.24 |
"Methane output was reported as methane in parts per million (ppm) on breath test:~Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration." (NCT00945334)
Timeframe: Baseline (Day 0) and Final Visit (Day 44)
| Intervention | parts per million (Median) |
|---|---|
| Group 1 | 7.5 |
| Group 2 | 15 |
"Visual analog scale (VAS) score for constipation:~Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms)." (NCT00945334)
Timeframe: 1 year
| Intervention | units on a scale (Mean) |
|---|---|
| Group 1 | 61.2 |
| Group 2 | 28.6 |
4 reviews available for methane and Colitis, Mucous
| Article | Year |
|---|---|
The importance of methane breath testing: a review.
Topics: Breath Tests; Exhalation; Humans; Irritable Bowel Syndrome; Lactose Intolerance; Methane | 2013 |
[Lactose intolerance: past and present. Part 1].
Topics: Animals; Biopsy; Breath Tests; Celiac Disease; Europe; Genetic Testing; Global Health; History, 17th | 2015 |
Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
Topics: Archaea; Constipation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irritable Bowel Syndr | 2016 |
Inflammation and microflora.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Enterobacteriaceae; Gastroenteritis; Gastrointestin | 2011 |
13 trials available for methane and Colitis, Mucous
| Article | Year |
|---|---|
A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth.
Topics: Anti-Bacterial Agents; Breath Tests; Constipation; Fasting; Glucose; Humans; Irritable Bowel Syndrom | 2022 |
Effect of Rice, Wheat, and Mung Bean Ingestion on Intestinal Gas Production and Postprandial Gastrointestinal Symptoms in Non-Constipation Irritable Bowel Syndrome Patients.
Topics: Adult; Breath Tests; Cross-Over Studies; Diet; Female; Humans; Irritable Bowel Syndrome; Male; Metha | 2019 |
Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome.
Topics: Adolescent; Breath Tests; Child; Cross-Over Studies; Diarrhea; Dietary Supplements; Double-Blind Met | 2018 |
Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome.
Topics: Adult; Breath Tests; Cultured Milk Products; Endpoint Determination; Fasting; Female; Gastrointestin | 2019 |
Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test.
Topics: Abdominal Pain; Adult; Area Under Curve; Breath Tests; Female; Flatulence; Gases; Humans; Hydrogen; | 2013 |
Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test.
Topics: Adolescent; Adult; Aged; Biomarkers; Breath Tests; Dietary Carbohydrates; Female; Fructose; Humans; | 2013 |
Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Topics: Adult; Anti-Infective Agents; Breath Tests; Constipation; Female; Gastrointestinal Agents; Humans; I | 2014 |
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.
Topics: Adolescent; Adult; Aged; Blind Loop Syndrome; Breath Tests; Diarrhea; Female; Glucose; Humans; Hydro | 2014 |
Lactulose Breath Test Gas Production in Childhood IBS Is Associated With Intestinal Transit and Bowel Movement Frequency.
Topics: Abdominal Pain; Adolescent; Biomarkers; Breath Tests; Child; Defecation; Depression; Female; Gastroi | 2017 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Breath Tests; Cross-Over Studies; Diet Records; Diet, Carbohydrate-Rest | 2010 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
The degree of breath methane production in IBS correlates with the severity of constipation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Breath Tests; Case-Control Studies; Constipation; Dou | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Fem | 2007 |
31 other studies available for methane and Colitis, Mucous
| Article | Year |
|---|---|
Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome.
Topics: Abdominal Pain; Humans; Hydrogen; Irritable Bowel Syndrome; Lactulose; Methane; Nausea | 2023 |
Hydrogen and methane breath test results are negatively associated with IBS and may reflect transit time in post-surgical patients.
Topics: Adult; Aged; Body Mass Index; Breath Tests; Digestive System Surgical Procedures; Female; Gastrointe | 2021 |
Methane and fatty acid metabolism pathways are predictive of Low-FODMAP diet efficacy for patients with irritable bowel syndrome.
Topics: Bacteria; Diet, Carbohydrate-Restricted; Fatty Acids, Volatile; Feces; Gastrointestinal Microbiome; | 2021 |
Correlation between small intestinal bacterial overgrowth and irritable bowel syndrome and the prognosis of treatment.
Topics: Anti-Bacterial Agents; Breath Tests; Humans; Intestine, Small; Irritable Bowel Syndrome; Methane | 2021 |
Small Intestinal Bacterial Overgrowth In Various Functional Gastrointestinal Disorders: A Case-Control Study.
Topics: Adult; Breath Tests; Case-Control Studies; Constipation; Humans; Intestine, Small; Irritable Bowel S | 2022 |
Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation.
Topics: Animals; Anticholesteremic Agents; Chemistry, Pharmaceutical; Constipation; Dogs; Drug Delivery Syst | 2018 |
A Pilot Study of the Effect of Green Kiwifruit on Human Intestinal Fermentation Measured by Hydrogen and Methane Breath Testing.
Topics: Actinidia; Adolescent; Adult; Breath Tests; Female; Fermentation; Fruit; Humans; Hydrogen; Intestina | 2018 |
Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.
Topics: Breath Tests; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Methane | 2020 |
Breath Methane Excretion Is not An Accurate Marker of Colonic Methane Production in Irritable Bowel Syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Breath Tests; Case-Control Studies; Cohort S | 2015 |
Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Bacteroides; Butyrates; Case-Control Stu | 2015 |
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Constipation; Diarrhea; Fema | 2016 |
Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome.
Topics: Adolescent; Adult; Biota; Breath Tests; Feces; Female; Gastrointestinal Transit; Humans; Hydrogen; I | 2016 |
Does Carbohydrate Challenge Testing Predict Clinical Response in Small Intestinal Bacterial Overgrowth?
Topics: Anti-Bacterial Agents; Breath Tests; Female; Gastrointestinal Agents; Humans; Hydrogen; Intestine, S | 2016 |
Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in
Topics: Adult; Aged; Area Under Curve; Breath Tests; Case-Control Studies; Constipation; Diarrhea; Feces; Fe | 2016 |
Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome.
Topics: Adult; Bacteroides; Breath Tests; Case-Control Studies; Clostridiales; DNA, Bacterial; Feces; Female | 2017 |
Effect of predominant methanogenic flora on outcome of lactose hydrogen breath test in controls and irritable bowel syndrome patients of north India.
Topics: Adolescent; Adult; Aged; Bacteria, Anaerobic; Breath Tests; Confounding Factors, Epidemiologic; Fema | 2009 |
Evaluating breath methane as a diagnostic test for constipation-predominant IBS.
Topics: Adult; Breath Tests; Constipation; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Irrit | 2010 |
Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study.
Topics: Adolescent; Bacterial Infections; Breath Tests; Case-Control Studies; Child; Child, Preschool; Comor | 2009 |
Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS.
Topics: Adult; Aged; Colon; Constipation; Feces; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; | 2010 |
A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; | 2010 |
Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?
Topics: Adult; Aged; Aged, 80 and over; Female; Flatulence; Gases; Humans; Hydrogen; Intestine, Small; Irrit | 2010 |
Fiber, FODMAPs, flora, flatulence, and the functional bowel disorders.
Topics: Abdominal Pain; Diet, Carbohydrate-Restricted; Dietary Carbohydrates; Dietary Fiber; Fermentation; F | 2010 |
Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome.
Topics: Breath Tests; Constipation; Diarrhea; Factor Analysis, Statistical; Humans; Irritable Bowel Syndrome | 2011 |
Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Breath Tests; Diagnosis, Differential; Digestive Syste | 2011 |
Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath.
Topics: Adult; Breath Tests; Constipation; DNA, Bacterial; Feces; Female; Humans; Hydrogen; Irritable Bowel | 2012 |
Reassessment of the role of methane production between irritable bowel syndrome and functional constipation.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacteria; Breath Tests; Constipation; Defec | 2012 |
Methanogenesis in irritable bowel syndrome: a lot of hot air?
Topics: Colon; Humans; Irritable Bowel Syndrome; Methane; Methanobacteriaceae | 2012 |
Effect of predominant methanogenic flora on the outcome of lactose breath test in irritable bowel syndrome patients.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, Gas; Female; Humans; Hydrogen; Irritable Bowe | 2003 |
IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, High Pressure Liquid; Constipation; Diarrhea; | 2004 |
Intestinal gas in plain abdominal radiographs does not correlate with symptoms after lactulose challenge.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Female; Fermentation; Flatulence; Gases; H | 2007 |
Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India.
Topics: Adolescent; Adult; Aged; Bacteria, Anaerobic; Bacterial Infections; Breath Tests; Case-Control Studi | 2009 |